Thermosome names Sabine Hauck as chief technical officer

German clinical-stage cancer drug developer Thermosome has appointed Dr Sabine Hauck as chief technology officer (CTO).

Dr Sabine Hauck is a highly experienced biopharmaceutical professional. She has been working in the field of drug product development in biopharma and specialty pharma for more than 20 years. Notably, she brings more than a decade of experience with liposomal products. Her expertise covers process development, chemistry, manufacturing and controls as well as bioanalytics, quality management and regulatory affairs.

Dr Hauck joins Thermosome from Leukocare AG, where she was executive vice president corporate development. During her professional career, which has included roles at Medigene AG and IDEA AG, she was actively involved in bringing liposomal drug candidates into clinical Phase III studies and registration. She was also responsible for regulatory affairs and international registration procedures. She succeeds Thermosome's former dhief pperating officer, Dr Uwe Michaelis.